Method for delivering a cytokine using a colloidal metal
View Patent ↗In accordance with the present invention, a composition and method is provided that allows for the administration of a biologically-active factors to a human or animal. The present invention can be used to treat a disease with a biologically-active factor or combination of biologically-active factors, or can be used to safely vaccinate a human or animal against a biologically-active factor. It can also be used as a method for the delivery of biologically-active factors for the treatment of disease. Additionally, the present invention also includes a method of targeted drug delivery for the treatment of disease through the administration of custom complexes containing of one or more biologically active factors bound to a colloidal metal where at least one of the biologically-active factors is capable of binding a high affinity receptor on a cell surface.
1. A method comprising administering to a human or animal a composition comprising one or more cytokines, a target molecule and a colloidal metal, wherein said one or more cytokines and said target molecule are bound to said colloidal metal.
2. The method of claim 1 , wherein the one or more cytokines are selected from the group consisting of Interleukin-1a (“IL-1a”), Interleukin-1B (“IL-1β”), Interleukin-2 (“IL-2”), Interleukin-3 (“IL-3”), Interleukin-4 (“IL-4”), Interleukin-5 (“IL-5”), Interleukin-6 (“IL-6”), Interleukin-7 (“IL-7”), Interleukin-8 (“IL-8”), Interleukin-9 (“IL-9”), Interleukin-10 (“IL-10”), Interleukin-11 (“IL-11”), Interleukin-12 (“IL-12”), Interleukin-13 (“IL-13”), Type I Interferon, Type II Interferon, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor (“CSF”), Monocyte-Macrophage CSF, and Granulocyte CSF.
3. The method of claim 1 , wherein the target molecule is selected from the group consisting of Tumor Necrosis Factor (“TNFα”), Transforming Growth Factor-β (“TGFβ), Migration Inhibition Factor, vascular endothelial growth factor (“VEGF”), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polycolonal antibodies, cancer cell specific antigen, and transforming growth factor alpha (“TGFα”).
4. The method of claim 3 , wherein the target molecule is a cancer cell specific antigen.
5. The method of claim 4 , wherein the cancer cell specific antigen is MART, MAGE, or BAGE.
6. The method of claim 3 , wherein the target molecule is a polyclonal or monoclonal antibody.